A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus

Journal of Viral Hepatitis

Volumn 22, Issue 12, 2015, Pages 1011-1019

  Lawitz, E ^a   Freilich, B ^b   Link, J ^c   German, P ^c   Mo, H ^c   Han, L ^c   Brainard, D M ^c   McNally, J ^c   Marbury, T ^d   Rodriguez Torres, M ^e  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Kansas City Gastroenterology and Hepatology   (United States)

^c GILEAD SCIENCES   (United States)

^d ORLANDO CLINICAL RESEARCH CENTER   (United States)

^e Fundacion de Investigacion   (Puerto Rico)

Author keywords

GS 5816; hepatitis C virus; NS5A inhibitor

Indexed keywords

NONSTRUCTURAL PROTEIN 5A; PLACEBO; VELPATASVIR; VIRUS RNA; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE; FUSED HETEROCYCLIC RINGS; NS-5 PROTEIN, HEPATITIS C VIRUS; VIRUS PROTEIN;

ADULT; AGED; AMINO ACID SEQUENCE; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; ELIMINATION HALF-LIFE; ELIMINATION RATE CONSTANT; FEMALE; GENETIC POLYMORPHISM; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM; YOUNG ADULT;

ADULT; AGED; ANTIVIRAL AGENTS; CARBAMATES; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; MALE; MIDDLE AGED; PLACEBOS; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, VIRAL; VIRAL NONSTRUCTURAL PROTEINS; YOUNG ADULT;

EID: 84945461800     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12435     Document Type: Article

References (15)

1. World Health Organization (WHO). Hepatitis C Fact sheet. Available at: http://www.who.int/mediacentre/factsheets/fs164/en/ #. (accessed 3 September 2014).
2. Wise M, Bialek S, Finelli L, Bell BP, Sorvillo F,. Changing trends in hepatitis C-related mortality in the United States, 1995-2004. Hepatology 2008; 47: 1128-1135.
3. Smith DB, Bukh J, Kuiken C,. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 2014; 59: 318-327.
4. Gower E, Estes C, Hindman S, Razavi-Shearer K, Razavi H,. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014; 61: S45-S57.
5. Lemoine M, Thursz M, Hepatitis C,. A global issue: access to care and new therapeutic and preventive approaches in resource-constrained areas. Semin Liver Dis 2014; 34: 89-97.
6. Cheng G, Yu M, Peng B, et al,. GS-5816, A novel second generation HCV NS5A inhibitor with preclinical pan-genotypic antiviral activity and a high resistance barrier [poster 1191]. J Hepatol 2013; 58 (Suppl.): EASL abstracts S484.
7. German P, Mathias AA, Pang PS, et al,. Healthy volunteer first-in-human evaluation of GS-5816, a novel second generation broad-genotypic NS5A inhibitor with potential for once-daily dosing European Association for the Study of the Liver, The Netherlands [Poster 1195]. J Hepatol 2013; 58 (Suppl.): S486.
8. Mogalian E, German P, Brainard D, et al,. Lack of a clinically significant pharmacokinetic drug-drug interaction between sofosbuvir and GS-5816 in healthy volunteers [poster465] The Liver Meeting® 2013: 64th Annual Meeting of the American Association for the Study of Liver Diseases, November 1-5, 2013, Washington DC, USA. Hepatology 2013; 58 (4) (Suppl AASLD abstracts) 431A.
9. Poveda E, Wyles DL, Mena A, Pedreira JD, Castro-Iglesias A, Cachay E,. Update on hepatitis C virus resistance do direct acting antiviral agents. Antivir Res 2014; 108: 182-191.
10. Pawlotsky JM,. NS5A inhibitors in the treatment of hepatitis C. J Hepatol 2013; 59: 375-382.
11. Mayers DL, Vince B, Hill JM, et al,. IDX719, HCV NS5A inhibitor, demonstrates pan-genotypic activity after three days of monotherapy in genotype 1, 2, 3 or 4 HCV-infected subjects; [poster 1774] Hepatology 2012; 56 (4) (Suppl AASLD abstracts) 1020A.
12. Lalezari JP, Farell GC, Shah PS, et al,. PPI-668, a potent new pan-genotypic HCV NS5A inhibitor: phase 1 efficacy and safety; [poster 1874] Hepatology 2012; 56 (4) (Suppl AASLD abstracts) 1065A.
13. Afdhal N, Zeuzem S, Kwo P, et al,. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-1898.
14. Kowdley KV, Gordon SC, Reddy KR, et al,. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-1888.
15. Ford N, Singh K, Cooke GS, et al,. Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS. Clin Infect Dis 2012; 54: 1465-1472.